CN114045233B - Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof - Google Patents
Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof Download PDFInfo
- Publication number
- CN114045233B CN114045233B CN202111293299.0A CN202111293299A CN114045233B CN 114045233 B CN114045233 B CN 114045233B CN 202111293299 A CN202111293299 A CN 202111293299A CN 114045233 B CN114045233 B CN 114045233B
- Authority
- CN
- China
- Prior art keywords
- parts
- bowel syndrome
- irritable bowel
- fermentation
- bla80
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 114
- 230000004151 fermentation Effects 0.000 title claims abstract description 114
- 208000002551 irritable bowel syndrome Diseases 0.000 title claims abstract description 107
- 206010010774 Constipation Diseases 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 28
- 239000002068 microbial inoculum Substances 0.000 title claims description 13
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 68
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 67
- 241000194020 Streptococcus thermophilus Species 0.000 claims abstract description 57
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 claims abstract description 56
- 229940004208 lactobacillus bulgaricus Drugs 0.000 claims abstract description 56
- 239000002054 inoculum Substances 0.000 claims abstract description 29
- 235000021107 fermented food Nutrition 0.000 claims abstract description 14
- 239000003223 protective agent Substances 0.000 claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 77
- 235000010469 Glycine max Nutrition 0.000 claims description 59
- 244000068988 Glycine max Species 0.000 claims description 58
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 54
- 235000013336 milk Nutrition 0.000 claims description 50
- 210000004080 milk Anatomy 0.000 claims description 50
- 239000008267 milk Substances 0.000 claims description 49
- 235000011187 glycerol Nutrition 0.000 claims description 27
- 239000007858 starting material Substances 0.000 claims description 27
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 25
- 229930006000 Sucrose Natural products 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 22
- 238000012258 culturing Methods 0.000 claims description 21
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 19
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 19
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 19
- 239000005720 sucrose Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 17
- 229920000858 Cyclodextrin Polymers 0.000 claims description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
- 239000001116 FEMA 4028 Substances 0.000 claims description 16
- 229930195725 Mannitol Natural products 0.000 claims description 16
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 16
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 16
- 229960004853 betadex Drugs 0.000 claims description 16
- 239000000594 mannitol Substances 0.000 claims description 16
- 235000010355 mannitol Nutrition 0.000 claims description 16
- 239000005913 Maltodextrin Substances 0.000 claims description 15
- 229920002774 Maltodextrin Polymers 0.000 claims description 15
- 229940035034 maltodextrin Drugs 0.000 claims description 15
- 229920001817 Agar Polymers 0.000 claims description 13
- 230000003213 activating effect Effects 0.000 claims description 13
- 239000008272 agar Substances 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 235000010419 agar Nutrition 0.000 claims description 12
- 239000001814 pectin Substances 0.000 claims description 12
- 235000010987 pectin Nutrition 0.000 claims description 12
- 229920001277 pectin Polymers 0.000 claims description 12
- 241000207199 Citrus Species 0.000 claims description 11
- 235000020971 citrus fruits Nutrition 0.000 claims description 11
- 239000000835 fiber Substances 0.000 claims description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 9
- 238000004321 preservation Methods 0.000 claims description 8
- 235000013312 flour Nutrition 0.000 claims description 7
- 235000020197 coconut milk Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 244000046052 Phaseolus vulgaris Species 0.000 claims description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 235000015140 cultured milk Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 238000010899 nucleation Methods 0.000 claims 1
- 235000013322 soy milk Nutrition 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 36
- 208000024891 symptom Diseases 0.000 abstract description 20
- 208000004998 Abdominal Pain Diseases 0.000 abstract description 16
- 230000013872 defecation Effects 0.000 abstract description 13
- 230000001105 regulatory effect Effects 0.000 abstract description 13
- 230000000968 intestinal effect Effects 0.000 abstract description 9
- 230000007413 intestinal health Effects 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 3
- 241000186672 Lactobacillus delbrueckii subsp. bulgaricus Species 0.000 abstract 2
- 239000000047 product Substances 0.000 description 36
- 230000000694 effects Effects 0.000 description 26
- 230000000052 comparative effect Effects 0.000 description 24
- 229960004793 sucrose Drugs 0.000 description 18
- 229940074410 trehalose Drugs 0.000 description 18
- 239000000203 mixture Substances 0.000 description 17
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 15
- 229920000053 polysorbate 80 Polymers 0.000 description 15
- 239000003814 drug Substances 0.000 description 14
- 206010000060 Abdominal distension Diseases 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000009630 liquid culture Methods 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 229960005150 glycerol Drugs 0.000 description 8
- 229960001855 mannitol Drugs 0.000 description 8
- 244000060011 Cocos nucifera Species 0.000 description 7
- 235000013162 Cocos nucifera Nutrition 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 235000021552 granulated sugar Nutrition 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 238000010008 shearing Methods 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 5
- 235000014655 lactic acid Nutrition 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 229940112824 paste Drugs 0.000 description 4
- 239000006072 paste Substances 0.000 description 4
- 239000002002 slurry Substances 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000009777 vacuum freeze-drying Methods 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 2
- 244000183685 Citrus aurantium Species 0.000 description 2
- 235000007716 Citrus aurantium Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000019790 abdominal distention Diseases 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940068140 lactobacillus bifidus Drugs 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- KJFMBFZCATUALV-UHFFFAOYSA-N phenolphthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2C(=O)O1 KJFMBFZCATUALV-UHFFFAOYSA-N 0.000 description 2
- 239000006041 probiotic Substances 0.000 description 2
- 235000018291 probiotics Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 240000008027 Akebia quinata Species 0.000 description 1
- 235000007756 Akebia quinata Nutrition 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 244000247747 Coptis groenlandica Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000221079 Euphorbia <genus> Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 240000000950 Hippophae rhamnoides Species 0.000 description 1
- 235000003145 Hippophae rhamnoides Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000218378 Magnolia Species 0.000 description 1
- 241001673966 Magnolia officinalis Species 0.000 description 1
- 235000013939 Malva Nutrition 0.000 description 1
- 240000000982 Malva neglecta Species 0.000 description 1
- 235000000060 Malva neglecta Nutrition 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000248825 Peltandra virginica Species 0.000 description 1
- 235000001188 Peltandra virginica Nutrition 0.000 description 1
- 235000008599 Poria cocos Nutrition 0.000 description 1
- 241001409305 Siraitia Species 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 235000019643 salty taste Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1238—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt using specific L. bulgaricus or S. thermophilus microorganisms; using entrapped or encapsulated yoghurt bacteria; Physical or chemical treatment of L. bulgaricus or S. thermophilus cultures; Fermentation only with L. bulgaricus or only with S. thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L11/00—Pulses, i.e. fruits of leguminous plants, for production of food; Products from legumes; Preparation or treatment thereof
- A23L11/50—Fermented pulses or legumes; Fermentation of pulses or legumes based on the addition of microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/123—Bulgaricus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Botany (AREA)
- Agronomy & Crop Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention relates to a direct-vat-set fermentation inoculant for relieving constipation type irritable bowel syndrome, and a preparation method and application thereof, wherein the direct-vat-set fermentation inoculant for relieving constipation type irritable bowel syndrome comprises streptococcus thermophilus ST81 fermented product, lactobacillus bulgaricus LB42 fermented product, bifidobacterium lactis BLa80 fermented product and a protective agent. The bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome, and is combined with streptococcus thermophilus ST81 and lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups are mutually promoted, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups are mutually matched, the bifidobacterium lactis Bla80 has a remarkable synergistic effect on regulating intestinal bacterial groups and relieving constipation type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, so that defecation is smoother, and constipation type irritable bowel syndrome is effectively relieved.
Description
Technical Field
The invention belongs to the technical field of food processing, relates to a direct-vat-set fermentation inoculant, a preparation method and application thereof, and in particular relates to a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, and a preparation method and application thereof.
Background
Irritable bowel syndrome (irritable bowel syndrome, IBS) is a group of continuous or intermittent episodes that change from abdominal pain, bloating, bowel habits and/or stool traits to clinical manifestations, lacking gastrointestinal structural and biochemical abnormalities in intestinal dysfunction. Constipation-predominant irritable bowel syndrome (IBS-C) is one of the more common types of irritable bowel syndrome. Patients may develop a series of digestive tract symptoms such as abdominal pain, abdominal distention, abdominal discomfort, etc., and may also be accompanied by psychological problems such as anxiety, depression, etc. At present, the constipation type irritable bowel syndrome is mainly treated by medicaments.
For example, CN112843143a discloses a traditional Chinese medicine composition for treating constipation type irritable bowel syndrome, and its medicament and application, the raw materials composition is as follows: magnolia bark, magnolia flower, immature bitter orange, sea buckthorn, kelp, fructus cannabis, bighead atractylodes rhizome, chinese angelica, fructus aurantii, cistanche and mulberry. The composition is prepared into a common pharmaceutical formulation by adding pharmaceutically conventional auxiliary materials according to a pharmaceutically conventional process. The traditional Chinese medicine composition disclosed by the invention has definite curative effects on constipation type irritable bowel syndrome in animal experiments and clinical symptoms.
CN109731092a discloses a traditional Chinese medicine composition for treating constipation type irritable bowel syndrome and a preparation method thereof. The composition comprises the following raw materials: bupleurum, immature bitter orange, white paeony root, hemp seed, betel nut, coptis root, garden euphorbia herb, fiveleaf akebia fruit, malva seed, dried ginger, tuckahoe, grosvener siraitia and liquorice. The medicines are matched according to a specific weight proportion, so that the medicine can treat both liver and spleen, tonify and concurrent, and both principal and secondary aspects of the disease are achieved, the effects of resolving turbidity and detoxifying, and clearing viscera and discharging turbidity are achieved, the symptoms of constipation, abdominal pain and the like of IBS-C can be effectively improved, the curative effect is clear, the cure rate is high, the recurrence rate is low, the price is low, and the treatment cost of IBS-C can be reduced.
The drug therapy disclosed in the prior art has good treatment effect on constipation type irritable bowel syndrome, however, the drug therapy often causes a certain degree of dependence, once a patient stops using the drug, constipation recurs, and the drug therapy may generate side effects such as headache, abdominal pain, diarrhea, cardiovascular diseases and the like.
Therefore, how to develop a new method of non-drug treatment for constipation-predominant irritable bowel syndrome is a problem to be solved by those skilled in the art.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a direct-vat-set fermentation inoculant, a preparation method and application thereof, and particularly provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, and a preparation method and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides a direct-vat-set starter for relieving constipation-predominant irritable bowel syndrome, which comprises a streptococcus thermophilus ST81 ferment, a lactobacillus bulgaricus LB42 ferment, a bifidobacterium lactis BLa80 ferment and a protective agent.
The invention creatively combines the streptococcus thermophilus ST81 ferment, the lactobacillus bulgaricus LB42 ferment and the bifidobacterium lactis Bla80 ferment to form the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome. The bifidobacterium lactis belongs to probiotics, can play a role in regulating intestinal flora by directly supplementing probiotics in vivo, and can inhibit the growth of harmful flora, so that the intestinal tract maintains a normal microenvironment, and the intestinal tract health is facilitated. It has certain regulating effect on functional enteropathy including irritable bowel syndrome, intestinal dysfunction, chronic diarrhea, abdominal distention and even chronic constipation. The streptococcus thermophilus is lactic acid bacteria, has the effects of improving the microbial environment of the gastrointestinal tract, reducing the pH value of the intestinal tract, promoting intestinal peristalsis, preventing the colonization of pathogenic bacteria, secreting bacteriocin to inhibit the growth of the pathogenic bacteria, inhibiting the activity of cholesterol synthase and reducing the cholesterol content in serum. The fermentation product can regulate and control blood pressure, and the products such as polysaccharide, bacteriocin, lactic acid and the like produced by fermentation have the effect of anti-tumor activity, and can resist tumor occurrence by activating an organism immune system and inhibiting cell mutation, and the superoxide dismutase produced by fermentation can remove excessive superoxide anion free radicals produced in the in-vivo metabolic process and delay aging. The lactobacillus bulgaricus also belongs to lactobacillus, has the effects of helping lactose fermentation and promoting digestion and absorption, can inhibit the growth and development of harmful flora in intestinal tracts, has the effect of regulating the intestinal flora, can activate the immune function in the intestinal tracts, can inhibit cancer cell proliferation, and has certain anti-inflammatory and antibacterial effects. In the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, the bifidobacterium lactis BLa80 plays a key role in regulating intestinal health and relieving constipation-type irritable bowel syndrome, and is combined with the streptococcus thermophilus ST81 and the lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups mutually promote, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups mutually cooperate, the direct-vat-set fermentation inoculant has a remarkable synergistic effect on regulating intestinal bacterial groups and relieving constipation-type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, so that defecation is smoother, and constipation-type irritable bowel syndrome is effectively relieved.
Preferably, the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome comprises, by weight, 25-45 parts of streptococcus thermophilus ST81 ferment, 1.5-2.5 parts of lactobacillus bulgaricus LB42 ferment, 2.5-65 parts of bifidobacterium lactis BLa80 ferment and 18-36 parts of protective agent.
Specific values of the 25 to 45 parts may be 25 parts, 27 parts, 29 parts, 31 parts, 33 parts, 35 parts, 37 parts, 39 parts, 41 parts, 43 parts, 45 parts, and the like.
Specific values of the above 1.5 to 2.5 parts may be 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, 2.5 parts, etc.
Specific values of the above 2.5 to 65 parts may be 2.5 parts, 3 parts, 3.5 parts, 4 parts, 8 parts, 12 parts, 16 parts, 20 parts, 24 parts, 28 parts, 32 parts, 36 parts, 40 parts, 44 parts, 48 parts, 52 parts, 56 parts, 60 parts, 62 parts, 65 parts, and the like.
Specific values of the 18-36 parts may be 18 parts, 19 parts, 20 parts, 21 parts, 22 parts, 23 parts, 24 parts, 25 parts, 26 parts, 27 parts, 28 parts, 29 parts, 30 parts, 31 parts, 32 parts, 33 parts, 34 parts, 35 parts, 36 parts, and the like.
Preferably, the viable count of bifidobacterium lactis BLa80 in the direct-vat-set fermentation starter for relieving constipation-predominant irritable bowel syndrome is 1×10 11 cfu/g or more, e.g. 1X 10 11 cfu/g、2×10 11 cfu/g、3×10 11 cfu/g、 4×10 11 cfu/g、6×10 11 cfu/g、8×10 11 cfu/g、9×10 11 cfu/g、1×10 12 cfu/g, etc.
Preferably, the protecting agent includes any one or a combination of at least two of trehalose, maltodextrin, beta-cyclodextrin, sucrose, glycerol, mannitol or tween-80, for example, a combination of trehalose and maltodextrin, a combination of beta-cyclodextrin and sucrose, a combination of sucrose and glycerol, etc., and any other combination is optional, and will not be described herein, preferably trehalose, maltodextrin, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80.
The combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 as a protective agent has the effect of improving the stability of the prepared fermented food compared with other options.
Preferably, the protective agent comprises 12-18 parts by weight of trehalose, 2.5-8.5 parts by weight of maltodextrin, 1.0-1.5 parts by weight of beta-cyclodextrin, 2-5 parts by weight of sucrose, 1.2-2.4 parts by weight of glycerol, 0.01-0.3 part by weight of mannitol and 0.02-0.25 part by weight of tween-80.
Specific values of the above 12 to 18 parts may be 12 parts, 12.5 parts, 13 parts, 13.5 parts, 14 parts, 14.5 parts, 15 parts, 15.5 parts, 16 parts, 16.5 parts, 17 parts, 17.5 parts, 18 parts, etc.
Specific values among the above 2.5 to 8.5 parts may be 2.5 parts, 2.7 parts, 3 parts, 3.2 parts, 3.5 parts, 3.7 parts, 4 parts, 4.2 parts, 4.5 parts, 4.7 parts, 5 parts, 5.2 parts, 5.5 parts, 5.7 parts, 6 parts, 6.2 parts, 6.5 parts, 6.7 parts, 7 parts, 7.2 parts, 7.5 parts, 7.7 parts, 8 parts, 8.2 parts, 8.5 parts, etc.
Specific values of the above 1.0 to 1.5 parts may be 1 part, 1.15 parts, 1.2 parts, 1.25 parts, 1.3 parts, 1.35 parts, 1.4 parts, 1.45 parts, 1.5 parts, etc.
Specific values of the above 2 to 5 parts may be 2 parts, 2.2 parts, 2.5 parts, 2.7 parts, 3 parts, 3.2 parts, 3.5 parts, 3.7 parts, 4 parts, 4.2 parts, 4.5 parts, 4.7 parts, 5 parts, etc.
Specific values of the above 1.2 to 2.4 parts may be 1.2 parts, 1.3 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.7 parts, 1.8 parts, 1.9 parts, 2 parts, 2.1 parts, 2.2 parts, 2.3 parts, 2.4 parts, etc.
Specific values of the above 0.01 to 0.3 parts may be 0.01 part, 0.03 part, 0.05 part, 0.07 part, 0.1 part, 0.12 part, 0.15 part, 0.17 part, 0.2 part, 0.22 part, 0.25 part, 0.27 part, 0.3 part, and the like.
Specific values among the above 0.02 to 0.25 parts may be 0.02 part, 0.04 part, 0.06 part, 0.08 part, 0.1 part, 0.12 part, 0.15 part, 0.17 part, 0.2 part, 0.22 part, 0.25 part, and the like.
In a second aspect, the present invention provides a method for preparing a direct-vat set fermentation starter for alleviating constipation-predominant irritable bowel syndrome according to the first aspect, the method comprising the steps of:
(1) Culturing and activating Streptococcus thermophilus ST81, and fermenting to obtain Streptococcus thermophilus ST81 fermented product; culturing and activating Lactobacillus bulgaricus LB42, and fermenting to obtain Lactobacillus bulgaricus LB42 fermented product; culturing and activating the bifidobacterium lactis BLa80, and fermenting to obtain a bifidobacterium lactis BLa80 fermentation product;
(2) Mixing the streptococcus thermophilus ST81 fermentation product, the lactobacillus bulgaricus LB42 fermentation product and the bifidobacterium lactis Bla80 fermentation product obtained in the step (1) with a protective agent to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Preferably, the temperature of the culture of Streptococcus thermophilus ST81, the temperature of the culture of Lactobacillus bulgaricus LB42 and the temperature of the culture of Bifidobacterium lactis Bla80 in step (1) are each independently 35-40 ℃, e.g., 35 ℃, 35.5 ℃, 36 ℃, 36.5 ℃, 37 ℃, 37.5 ℃, 38 ℃, 38.5 ℃, 39 ℃, 39.5 ℃, 40 ℃, etc.
Preferably, the time of the culture of Streptococcus thermophilus ST81, the time of the culture of Lactobacillus bulgaricus LB42 and the time of the culture of Bifidobacterium lactis Bla80 in step (1) are each independently 16-24 hours, such as 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, etc.
Preferably, the temperature of fermentation of Streptococcus thermophilus ST81, the temperature of fermentation of Lactobacillus bulgaricus LB42 and the temperature of fermentation of Bifidobacterium lactis BLa80 in step (1) are each independently 35-40 ℃, e.g. 35 ℃, 35.5 ℃, 36 ℃, 36.5 ℃, 37 ℃, 37.5 ℃, 38 ℃, 38.5 ℃, 39 ℃, 39.5 ℃, 40 ℃, etc.
Preferably, the fermentation time of Streptococcus thermophilus ST81, the fermentation time of Lactobacillus bulgaricus LB42 and the fermentation time of Bifidobacterium lactis Bla80 in step (1) are each independently 9-12h, such as 9h, 9.2h, 9.5h, 9.7h, 10h, 10.2h, 10.5h, 10.7h, 11h, 11.2h, 11.5h, 11.7h, 12h, etc.
Preferably, the pH of the system in step (1) in the fermentation of Streptococcus thermophilus ST81, the pH of the system in the fermentation of Lactobacillus bulgaricus LB42 and the pH of the system in the fermentation of Bifidobacterium lactis BLa80 are each independently 5.5-6.0, e.g. 5.5, 5.55, 5.6, 5.65, 5.7, 5.75, 5.8, 5.85, 5.9, 5.95, 6, etc.
Preferably, step (1) further optionally comprises centrifugation to collect fermentation products after fermentation of Streptococcus thermophilus ST81, after fermentation of Lactobacillus bulgaricus LB42 and after fermentation of Bifidobacterium lactis Bla 80.
Preferably, the rotational speed of the centrifugation is each independently 6000-10000r/min, e.g. 6000r/min, 6500r/min, 7000r/min, 7500r/min, 8000r/min, 8500r/min, 9000r/min, 9500 r/min, 10000r/min etc.
The centrifugation time is 10-15min, such as 10min, 10.5min, 11min, 11.5min, 12min, 12.5min, 13min, 13.5min, 14min, 14.5min, 15min, etc., independently.
Preferably, the mixing in step (2) further comprises drying.
Preferably, the drying mode is freeze drying.
In a third aspect, the present invention provides a use of a direct vat set starter for alleviating constipation-predominant irritable bowel syndrome according to the first aspect in the preparation of a fermented food, wherein the inoculum size of the direct vat set starter for alleviating constipation-predominant irritable bowel syndrome is 20-50g/T, e.g. 20g/T, 22g/T, 25g/T, 27g/T, 30g/T, 32g/T, 35g/T, 37g/T, 40g/T, 42g/T, 45g/T, 47g/T, 50g/T, etc. The T represents ton.
Preferably, the fermented food includes any one of fermented soybean milk, fermented soybean powder, fermented milk or fermented milk powder.
In a fourth aspect, the invention provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises soybean flour, gum base, water and a direct-vat-set starter for relieving constipation-predominant irritable bowel syndrome according to the first aspect.
Preferably, the preparation raw materials of the fermented soybean milk for relieving constipation-type irritable bowel syndrome comprise, by mass, 0.002-0.005% of a direct-vat starter for relieving constipation-type irritable bowel syndrome, 10-28% of soybean flour, 3-20% of a gum base and the balance of water.
Specific values of the above 0.002 to 0.005% may be 0.002%, 0.0022%, 0.0025%, 0.0027%, 0.003%, 0.0032%, 0.0035%, 0.0037%, 0.004%, 0.0042%, 0.0045%, 0.0047%, 0.005% and the like.
Specific values of the above 10 to 28% may be 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28% and the like.
Specific values in the above 3 to 20% may be 3%, 4%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20% and the like.
Preferably, the gum base includes any one or a combination of at least two of coconut pulp, white granulated sugar, agar, pectin, citrus fiber or sea salt, for example, a combination of coconut pulp and white granulated sugar, a combination of agar and pectin, a combination of pectin and citrus fiber, etc., and any other combination mode may be selected, which will not be described in detail herein, preferably a combination of coconut pulp, white granulated sugar, agar, pectin, citrus fiber and sea salt.
Preferably, the gum base comprises, by weight, 3-10 parts of coconut milk, 1-5 parts of white granulated sugar, 0.1-1 part of agar, 0.1-0.8 part of pectin, 0.2-0.8 part of citrus fiber and 0.01-0.1 part of sea salt.
Specific values of the 3-10 parts may be 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, 5.5 parts, 6 parts, 6.5 parts, 7 parts, 7.5 parts, 8 parts, 8.5 parts, 9 parts, 9.5 parts, 10 parts, etc.
Specific values of the above 1 to 5 parts may be 1 part, 1.5 parts, 2 parts, 2.5 parts, 3 parts, 3.5 parts, 4 parts, 4.5 parts, 5 parts, etc.
Specific values of the above 0.1 to 1 part may be 0.1 part, 0.2 part, 0.3 part, 0.4 part, 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1 part, etc.
Specific values among the above 0.1 to 0.8 parts may be 0.1 part, 0.15 part, 0.2 part, 0.25 part, 0.3 part, 0.35 part, 0.4 part, 0.45 part, 0.5 part, 0.55 part, 0.6 part, 0.65 part, 0.7 part, 0.75 part, 0.8 part, and the like.
Specific values of the above 0.2 to 0.8 parts may be 0.2 parts, 0.25 parts, 0.3 parts, 0.35 parts, 0.4 parts, 0.45 parts, 0.5 parts, 0.55 parts, 0.6 parts, 0.65 parts, 0.7 parts, 0.75 parts, 0.8 parts, etc.
Specific values among the above 0.01 to 0.1 parts may be 0.01 part, 0.015 part, 0.02 part, 0.025 part, 0.03 part, 0.035 part, 0.04 part, 0.045 part, 0.05 part, 0.055 part, 0.06 part, 0.065 part, 0.07 part, 0.075 part, 0.08 part, 0.085 part, 0.09 part, 0.095 part, 0.1 part, and the like.
In a fifth aspect, the present invention provides a method for preparing fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome according to the fourth aspect, the method comprising mixing bean flour, gum base and water, homogenizing, sterilizing, inoculating a direct-vat-set fermentation starter for alleviating constipation-predominant irritable bowel syndrome, fermenting, and demulsifying to obtain the fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome.
Preferably, the temperature of the mixing is 60-90 ℃, e.g., 60 ℃, 62 ℃, 65 ℃, 67 ℃, 70 ℃, 72 ℃, 75 ℃, 77 ℃, 80 ℃, 82 ℃, 85 ℃, 87 ℃, 90 ℃, etc.
Preferably, the inoculation temperature is 38-50deg.C, such as 38deg.C, 39deg.C, 40deg.C, 41 deg.C, 42 deg.C, 43 deg.C, 44 deg.C, 45 deg.C, 46 deg.C, 47 deg.C, 48 deg.C, 49 deg.C, 50 deg.C, etc.
Preferably, the fermentation temperature is 38-50deg.C, such as 38deg.C, 39deg.C, 40deg.C, 41 deg.C, 42 deg.C, 43 deg.C, 44 deg.C, 45 deg.C, 46 deg.C, 47 deg.C, 48 deg.C, 49 deg.C, 50 deg.C, etc.
The numerical ranges recited herein include not only the recited point values, but also any point values between the recited numerical ranges that are not recited, and are limited to, and for the sake of brevity, the invention is not intended to be exhaustive of the specific point values that the recited range includes.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively combines the streptococcus thermophilus ST81 ferment, the lactobacillus bulgaricus LB42 ferment and the bifidobacterium lactis Bla80 ferment to form the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome. The bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome, and is combined with streptococcus thermophilus ST81 and lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups are mutually promoted, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups are mutually matched, the effects of remarkable synergy are achieved on regulating intestinal bacterial groups and relieving constipation type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, enable defecation to be smoother, and effectively relieve constipation type irritable bowel syndrome. In addition, the invention adopts the specific combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 as the protective agent, thereby having the effect of improving the stability of the prepared fermented food.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following description will further describe the technical solution of the present invention in connection with the preferred embodiments of the present invention, but the present invention is not limited to the embodiments.
The streptococcus thermophilus ST81 related to the following examples, comparative examples, application examples and comparative application examples is preserved in the China general microbiological culture Collection center, which is classified and named as streptococcus thermophilus Streptococcus thermophilus, and has a preservation number of CGMCC No.15752, a preservation date of 2018.05.11 and a preservation address of Beichen Xiyang area Beichen Xiylu No.1 and 3.
The following examples, comparative examples, application examples and comparative application examples were collected in China general microbiological culture Collection center (China Committee for culture Collection of microorganisms), and were classified and named as De-type Lactobacillus bulgaricus Lactobacillus delbrueclii subsp.bulgaricus, which has a collection number of CGMCC No.15751, a collection date of 2018.05.11, and a collection address of North Chen West Lu No.1, 3 in the Chachiensis of Chachiensis.
The bifidobacterium lactis BLa80 of the following examples, comparative examples, application examples and comparative application examples is preserved in the general microbiological center of the China Committee for culture Collection of microorganisms, and is classified and named as bifidobacterium animalis subsp Bifidobacterium animalis subsp.Lactis, which is preserved with the number CGMCC No.15410, the preservation date is 2018.03.05, and the preservation address is North Chen West Lu No.1, 3 in the Yankee area of Beijing city.
Example 1
The embodiment provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which comprises, by weight, 30 parts of streptococcus thermophilus ST81 fermentation product, 1.5 parts of lactobacillus bulgaricus LB42 fermentation product, 2.5 parts of bifidobacterium lactis Bla80 fermentation product, 12.5 parts of trehalose, 4 parts of maltodextrin, 1 part of beta-cyclodextrin, 3 parts of sucrose, 1.5 parts of glycerol, 0.05 part of mannitol and 0.2 part of tween-80. Wherein the viable count of the bifidobacterium lactis BLa80 in the direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome is 1 multiplied by 10 11 cfu/g。
The preparation method comprises the following steps:
(1) Inoculating bifidobacterium lactis BLa80 stored in an glycerol pipe into an MRS liquid culture medium according to the proportion of 2%, standing and culturing for 22 hours at 37 ℃, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2%, culturing at pH 5.5 and 37 ℃ for 11h, collecting bacterial liquid, centrifuging at 10000r/min for 10min, removing supernatant, and collecting bacterial mud to obtain bifidobacterium lactis BLa80 fermentation product.
The streptococcus thermophilus ST81 preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to the proportion of 2 percent, and is subjected to stationary culture for 20 hours at 38 ℃ and activated for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 3%, culturing at pH 6.0 and 39 ℃ for 9h, collecting bacterial liquid, centrifuging at 8000r/min for 12min, discarding supernatant, and collecting bacterial mud to obtain Streptococcus thermophilus ST81 fermentation product.
Inoculating Lactobacillus bulgaricus LB42 stored in glycerol pipe into MRS liquid culture medium according to 2%, standing at 39deg.C for 18h, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2.5%, culturing for 10 hours at the pH of 5.8 and the temperature of 38 ℃, collecting bacterial liquid, centrifuging for 15 minutes at 6000r/min, removing supernatant fluid, and collecting bacterial mud to obtain the lactobacillus bulgaricus LB42 fermentation product.
(2) Uniformly mixing the bifidobacterium lactis BLa80 fermentation product, the streptococcus thermophilus ST81 fermentation product and the lactobacillus bulgaricus LB42 fermentation product obtained in the step (1) with trehalose, maltodextrin, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80, and performing vacuum freeze drying to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Example 2
The embodiment provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which comprises, by weight, 25 parts of streptococcus thermophilus ST81 fermentation product, 2 parts of lactobacillus bulgaricus LB42 fermentation product, 2.5 parts of bifidobacterium lactis BLa80 fermentation product, 14 parts of trehalose, 8 parts of maltodextrin, 1.5 parts of beta-cyclodextrin, 2 parts of sucrose, 2.2 parts of glycerin, 0.25 part of tween-80 and 0.05 part of mannitol.
The preparation method comprises the following steps:
(1) The streptococcus thermophilus ST81 preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to the proportion of 2 percent, and is subjected to stationary culture at 37 ℃ for 22 hours, and is activated for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2%, culturing at pH 5.5 and 37 ℃ for 11h, collecting bacterial liquid, centrifuging at 10000r/min for 10min, discarding supernatant, and collecting bacterial mud to obtain Streptococcus thermophilus ST81 ferment.
Inoculating Lactobacillus bulgaricus LB42 stored in glycerol pipe into MRS liquid culture medium according to 2%, standing at 38deg.C for 20 hr, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 3%, culturing at pH 6.0 and 39 ℃ for 9h, collecting bacterial liquid, centrifuging at 8000r/min for 12min, discarding supernatant, and collecting bacterial mud to obtain lactobacillus bulgaricus LB42 fermentation product.
Inoculating bifidobacterium lactis BLa80 stored in an glycerol pipe into an MRS liquid culture medium according to the proportion of 2%, standing and culturing for 18 hours at 39 ℃, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2.5%, culturing at pH 5.8 and 38deg.C for 10h, collecting bacterial liquid, centrifuging at 6000r/min for 15min, discarding supernatant, and collecting bacterial mud to obtain Bifidobacterium lactis BLa80 fermented product.
(2) Uniformly mixing the streptococcus thermophilus ST81 fermentation product, the lactobacillus bulgaricus LB42 fermentation product and the bifidobacterium lactis Bla80 fermentation product obtained in the step (1) with trehalose, maltodextrin, beta-cyclodextrin, sucrose, tween-80, glycerol and mannitol, and performing vacuum freeze drying to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Example 3
The embodiment provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which comprises, by weight, 32 parts of streptococcus thermophilus ST81 fermentation product, 1.5 parts of lactobacillus bulgaricus LB42 fermentation product, 2.5 parts of bifidobacterium lactis Bla80 fermentation product, 13 parts of trehalose, 3 parts of maltodextrin, 1.5 parts of beta-cyclic alexin, 2 parts of sucrose, 0.01 part of mannitol, 1 part of glycerol and 0.2 part of tween-80.
The preparation method comprises the following steps:
(1) Inoculating Lactobacillus bulgaricus LB42 stored in glycerol pipe into MRS liquid culture medium according to 2%, standing at 37deg.C for 22 hr, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2%, culturing at pH 5.5 and 37 ℃ for 11h, collecting bacterial liquid, centrifuging at 10000r/min for 10min, discarding supernatant, and collecting bacterial mud to obtain lactobacillus bulgaricus LB42 fermentation product.
Inoculating bifidobacterium lactis BLa80 stored in an glycerol pipe into an MRS liquid culture medium according to the proportion of 2%, standing and culturing for 20 hours at 38 ℃, and activating for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 3%, culturing at pH 6.0 and 39 ℃ for 9h, collecting bacterial liquid, centrifuging at 8000r/min for 12min, discarding supernatant, and collecting bacterial mud to obtain bifidobacterium lactis BLa80 fermented product.
The streptococcus thermophilus ST81 preserved by the glycerol pipe is inoculated into MRS liquid culture medium according to the proportion of 2 percent, and is subjected to stationary culture for 18 hours at 39 ℃ and activated for 3 generations. Inoculating the activated seeds into a fermentation tank with an inoculum size of 2.5%, culturing at pH 5.8 and 38deg.C for 10 hr, collecting bacterial liquid, centrifuging at 6000r/min for 15min, discarding supernatant, and collecting bacterial mud to obtain Streptococcus thermophilus ST81 ferment.
(2) Uniformly mixing the lactobacillus bulgaricus LB42 fermentation product, the bifidobacterium lactis BLa80 fermentation product and the streptococcus thermophilus ST81 fermentation product obtained in the step (1) with trehalose, sucrose, mannitol, maltodextrin, beta-cyclodextrin, glycerol and tween-80, and performing vacuum freeze drying to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
Example 4
The present example provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which is different from example 1 only in that 12.5 parts of trehalose, 4 parts of maltodextrin, 1 part of beta-cyclodextrin, 3 parts of sucrose, 1.5 parts of glycerin, 0.05 part of mannitol and 0.2 part of tween-80 in example 1 are replaced by 13 parts of trehalose, 5.25 parts of maltodextrin, 2 parts of sucrose and 2 parts of glycerin, and the other components and the content are unchanged.
The preparation method is described in example 1.
Example 5
The present example provides a direct-vat-set fermentation inoculant for relieving constipation-type irritable bowel syndrome, which is different from example 1 only in that 12.5 parts of trehalose, 4 parts of maltodextrin, 1 part of beta-cyclodextrin, 3 parts of sucrose, 1.5 parts of glycerin, 0.05 part of mannitol and 0.2 part of tween-80 are replaced by 15 parts of trehalose and 7.25 parts of maltodextrin in example 1, and other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 1
This comparative example provides a direct-vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Lactobacillus bifidus Bla80 ferment" of example 1 are replaced with 31.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Lactobacillus bifidus Bla80 ferment, and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 2
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment" of example 1 are replaced by 31.5 parts of the Streptococcus thermophilus ST81 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment, and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 3
This comparative example provides a direct-vat set starter which differs from example 1 only in that 30 parts of the Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment and 2.5 parts of the Bifidobacterium lactis Bla80 ferment of example 1 are replaced by 34 parts of the Streptococcus thermophilus ST81 ferment and Lactobacillus bulgaricus LB42 ferment combination, wherein the mass ratio of the Streptococcus thermophilus ST81 ferment to the Lactobacillus bulgaricus LB42 ferment is 20:1, and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 4
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment of example 1, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment are replaced by 2.5 parts of the" Bifidobacterium lactis Bla80 ferment ", and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 5
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the "Streptococcus thermophilus ST81 ferment of example 1, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment are replaced by 34 parts of the" Streptococcus thermophilus ST81 ferment ", and the other components and contents are unchanged.
The preparation method is described in example 1.
Comparative example 6
This comparative example provides a direct vat set starter which differs from example 1 only in that 30 parts of the Streptococcus thermophilus ST81 ferment, 1.5 parts of the Lactobacillus bulgaricus LB42 ferment, 2.5 parts of the Bifidobacterium lactis Bla80 ferment of example 1 are replaced by 34 parts of the Lactobacillus bulgaricus LB42 ferment, and the other components and contents are unchanged.
The preparation method is described in example 1.
Application example 1
The application example provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises, by mass, 0.003% of the direct-vat starter bacterial agent for relieving constipation-predominant irritable bowel syndrome of example 1, 17.5% of soybean meal, 5.5% of coconut milk, 2% of white granulated sugar, 1% of agar, 0.3% of pectin, 0.2% of citrus fiber, 0.03% of sea salt and the balance of water.
The preparation method comprises the following steps:
(1) Dissolving soybean powder in water, shearing at 80deg.C for 15min, standing for 10min, mixing, and heating to 90deg.C. Mixing agar, citrus fiber and white sugar at 70deg.C, shearing for 20min to dissolve, adding dissolved bean powder, coconut slurry, pectin and sea salt, and stirring.
(2) Homogenizing the mixture obtained in the step (1) at 60 ℃ and 20 MPa.
(3) Heating the homogenized mixture to 95 ℃ and preserving heat for 5min for sterilization.
(4) Cooling the sterilized mixture to 43 ℃, inoculating a direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome, fermenting at 44 ℃, stopping when the pH value of the system is below 4.5 and the acidity of the system is above 30 ℃, and demulsifying to obtain the fermented soybean milk for relieving constipation-type irritable bowel syndrome.
Application example 2
The application example provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises, by mass, 0.003% of the direct-vat fermentation microbial inoculum for relieving constipation-predominant irritable bowel syndrome of example 2, 25% of soybean meal, 3% of coconut slurry, 1% of white granulated sugar, 0.5% of agar, 0.1% of pectin, 0.5% of citrus fiber and the balance of water.
The preparation method comprises the following steps:
(1) Dissolving soybean powder in water, shearing at 70deg.C for 15min, standing for 10min, mixing, and heating to 80deg.C. Mixing agar, citrus fiber and white sugar at 60deg.C, shearing for 20min to dissolve, adding dissolved bean powder, pectin and coconut slurry, and stirring to obtain mixture.
(2) Homogenizing the mixture obtained in the step (1) at 65 ℃ and 20 MPa.
(3) Heating the homogenized mixture to 90 ℃ and preserving heat for 10min for sterilization.
(4) Cooling the sterilized mixture to 48 ℃, inoculating a direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome, fermenting at 47 ℃, stopping when the pH value of the system is below 4.5 and the acidity of the system is above 30 ℃, and demulsifying to obtain the fermented soybean milk for relieving constipation-type irritable bowel syndrome.
Application example 3
The application example provides fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which comprises, by mass, 0.003% of the constipation-predominant irritable bowel syndrome relieving direct-vat starter of the embodiment 3, 15% of soybean meal, 9.5% of coconut milk, 5% of white granulated sugar, 0.2% of agar and 0.08% of sea salt, and the balance of water.
The preparation method comprises the following steps:
(1) Dissolving soybean powder in water, shearing at 75deg.C for 15min, standing for 15min, mixing, and heating to 85deg.C. Mixing agar and white sugar at 65deg.C, shearing for 15min to dissolve, adding dissolved bean powder, coconut slurry and sea salt, and stirring to obtain mixture.
(2) Homogenizing the mixture obtained in the step (1) at 70 ℃ and 18 MPa.
(3) Heating the homogenized mixture to 90 ℃ and preserving heat for 10min for sterilization.
(4) And cooling the sterilized mixture to 38 ℃, inoculating a direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome, fermenting at 39 ℃, stopping when the pH value of the system is below 4.5 and the acidity of the system is above 30 ℃, and demulsifying to obtain the fermented soybean milk for relieving constipation-type irritable bowel syndrome.
Application examples 4 to 5
Application examples 4 to 5 provide two kinds of fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, which are different from application example 1 only in that "0.003% of the direct-vat starter for relieving constipation-predominant irritable bowel syndrome of example 1" is replaced by 0.003% of the direct-vat starter for relieving constipation-predominant irritable bowel syndrome of examples 4 to 5, respectively, and the other components and contents are unchanged.
The preparation method is described in application example 1.
Comparative application examples 1 to 6
Comparative application examples 1 to 6 provided six fermented soybean milks differing from application example 1 only in that "0.003% of the direct fermentation starter for relieving constipation-predominant irritable bowel syndrome of example 1" was replaced with "0.003% of the direct fermentation starter of comparative examples 1 to 6", respectively, and the other components and contents were unchanged.
The preparation method is described in application example 1.
Test example 1
Stability test:
viscosity and acidity are important indexes for evaluating the taste of the fermented soybean milk, and are also important indexes for evaluating the quality stability of the fermented soybean milk. The viable count of bifidobacterium lactis Bla80 is an important influencing factor for the efficacy of fermented soybean milk and the regulation of intestinal health. Thus, the fermented soybean milk of application examples 1 to 5 was tested for changes in viscosity, acidity, pH, total number of lactic acid bacteria and viable count of bifidobacterium lactis BLa80 at shelf life (21 days of cold storage at 10 ℃) as follows:
Acidity was measured using an acidity meter (titration with 0.101mol/L NaOH standard solution using phenolphthalein as an indicator). The pH was measured with a pH meter (METTLER TOLEDO pH meter). Product viscosity was measured using a viscometer (NDJ-8S).
The total number of viable lactic acid bacteria (i.e., the total number of viable streptococcus thermophilus and lactobacillus bulgaricus) and the total number of viable bifidobacteria (i.e., the number of viable bifidobacterium lactis BLa 80) were detected according to the method of national standard GB 4789.35-2016. The results are shown in Table 1.
TABLE 1
/>
The results show that: the fermented soybean milk provided in application examples 1-5 has smaller viscosity change in shelf life and more stable texture state. The acidity and pH of the fermented soybean milk change to a smaller extent overall, indicating that the flavor and taste are more stable. During the cold storage period, the total number of lactobacillus in the fermented soybean milk is reduced, the viable count of the bifidobacterium lactis BLa80 is stable, and the viable count reaches 3.0X10 7 Above cfu/g, thus, the crowd suffering from constipation-predominant irritable bowel syndrome can achieve the effects of regulating intestinal health and relieving constipation by only drinking 300g of the fermented soybean milk provided in application examples 1-5 each day. The viscosity change, acidity change and pH change degree of the fermented soybean milk provided in application examples 4 and 5 are slightly larger than those of application example 1, and the viable count of lactic acid bacteria and bifidobacterium lactis Bla80 is slightly lower than that of application example 1, which shows that the specific combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 is adopted as a protective agent to improve the stability of the prepared fermented soybean milk. In summary, application examples 1-5 are presented The viscosity, acidity and pH of the fermented soybean milk are less in change during refrigeration, the viable count of bifidobacterium lactis BLa80 in the fermented soybean milk is higher and stable, which indicates that the fermented soybean milk has better stability.
Test example 2
Safety evaluation:
the safety of the fermented soybean milk provided in application examples 1 to 5 was evaluated. 100 healthy volunteers (no allergy history to fermented soybean milk) were selected, and randomly divided into 5 groups of 20, each of the groups 1 to 5 taking 300ml of fermented soybean milk provided in application examples 1 to 5, respectively, per day. All volunteers did not take other drugs for treating gastrointestinal diseases and other fermented foods during the trial period. The test period was 1 month. And recording and comparing adverse reactions such as abdominal pain, abdominal distension, nausea and the like of each group of volunteers, and evaluating the safety of the fermented soybean milk.
The results show that: all volunteers do not have the phenomena of abdominal pain, abdominal distension, nausea and the like, which indicates that the fermented soybean milk provided in application examples 1-5 has no adverse reaction after being taken, and the safety meets the requirements.
Test example 3
Evaluation of effect of relieving constipation-predominant irritable bowel syndrome:
the fermented soybean milk provided in application examples 1 to 3 and comparative application examples 1 to 6 was evaluated for the alleviation of constipation-predominant irritable bowel syndrome. 100 volunteers with constipation type irritable bowel syndrome (including standard: according with related diagnosis standard of irritable bowel syndrome in Western medicine and Chinese medicine theory and confirmed diagnosis; volunteers have typical performances of constipation type irritable bowel syndrome; no allergic history to fermented soybean milk; understanding test content and participation in the test; excluding standard: having received other various medicines before starting the test, cardiovascular, renal and other organic lesions), were randomly divided into 10 groups of 10, each group of 1-9 was administered 300ml of fermented soybean milk provided in application examples 1-3 and comparative application examples 1-6, respectively, each group of 10 was a control group, and each person was administered 300ml of common commercial fermented soybean milk per day. The uniform drinking time of all volunteers was after breakfast and received uniform conventional diet regimen during the test period, including adjusting diet structure, increasing dietary salty taste and water intake, etc., without taking other drugs for treating gastrointestinal diseases and other fermented foods. The test period was 6 months.
Evaluation of curative effect: constipation symptoms and stool characteristics before and after taking fermented soybean milk by volunteers are observed, and the constipation symptom score is referred to a constipation symptom score table of the department of surgery of the Chinese medical society, which comprises 6 items of defecation difficulty, stool characteristics (BSS), defecation time, inexhaustible feeling, frequency and abdominal distension, wherein the score is set to 0-3, and the higher score indicates that the symptom is more serious. The volunteers of each group integrated for symptoms of abdominal distension, abdominal pain and bowel difficulty before and after the trialAre listed in Table 2. Data were processed using SPSS 20.0 statistical software, the metering data were t-checked, and the counting data were x 2 Checking, P<0.05 indicates that there is a statistical significance for the difference. The difference between symptom scores of the volunteers of each group before the test was not statistically significant (P>0.05)
TABLE 2
Comparing the clinical effects of each group: the curative effects are divided into cure, obvious effect, effective and ineffective. And (3) healing: the volunteers have normal defecation and normal stool texture, no abdominal distension and pain and no recurrence in 6 months; the effect is shown: the defecation condition and the stool texture of volunteers are obviously improved, the volunteers tend to be normal, most symptoms disappear, and recurrence is occasional within 6 months; the method is effective: the defecation condition and the stool texture of volunteers are improved, and the symptoms are reduced compared with those before treatment; invalidation: the volunteers had no improvement in defecation, stool texture, and abdominal distension and pain symptoms after treatment. The results are shown in Table 3.
TABLE 3 Table 3
The results show that: as can be seen from the data in tables 2 and 3, after the fermented soybean milk provided in application examples 1-3 is taken by constipation type irritable bowel syndrome patients, symptoms such as abdominal distension, abdominal pain and difficult defecation are obviously improved, which indicates that the fermented soybean milk provided in application examples 1-3 has an effect of remarkably relieving constipation type irritable bowel syndrome. The fermented soybean milk provided by comparative application examples 3, 5 and 6 does not contain bifidobacterium lactis Bla80, and only has a certain improvement effect on symptoms of abdominal distension after being taken, but can not relieve symptoms of abdominal pain, difficult defecation and the like of patients, and does not have the function of relieving constipation type irritable bowel syndrome, which means that bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome in the invention. The fermented soybean milk provided in application examples 1, 2 and 4 has a certain relieving effect on symptoms such as abdominal distension, abdominal pain and difficult defecation, but the effect is obviously inferior to that of application example 1, which shows that the three bacterial agents of streptococcus thermophilus ST81 ferment, lactobacillus bulgaricus LB42 ferment and bifidobacterium lactis BLa80 ferment are mutually matched and synergistically increased, and the fermented soybean milk has more remarkable effect on relieving constipation type irritable bowel syndrome than the independent combination of bifidobacterium lactis BLa80 ferment, streptococcus thermophilus ST81 ferment and bifidobacterium lactis BLa80 ferment and the combination of lactobacillus bulgaricus LB42 ferment and bifidobacterium lactis BLa80 ferment.
In summary, the invention creatively combines the streptococcus thermophilus ST81 ferment, the lactobacillus bulgaricus LB42 ferment and the bifidobacterium lactis Bla80 ferment to form the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome. The bifidobacterium lactis Bla80 plays a key role in regulating intestinal health and relieving constipation type irritable bowel syndrome, and is combined with streptococcus thermophilus ST81 and lactobacillus bulgaricus LB42, so that on one hand, three bacterial groups are mutually promoted, the fermentation process is facilitated, the growth of beneficial bacterial groups is promoted, on the other hand, the three bacterial groups are mutually matched, the bifidobacterium lactis Bla80 has a remarkable synergistic effect on regulating intestinal bacterial groups and relieving constipation type irritable bowel syndrome, and the prepared fermented food can improve symptoms such as constipation and abdominal pain, enable defecation to be smoother, and effectively relieve constipation type irritable bowel syndrome. In addition, the invention adopts the specific combination of trehalose, malt paste, beta-cyclodextrin, sucrose, glycerol, mannitol and tween-80 as the protective agent, and has the effect of improving the stability of the prepared fermented food.
The applicant states that the direct-vat set fermentation inoculant for relieving constipation-predominant irritable bowel syndrome and the preparation method and application thereof are described by the above examples and application examples, but the invention is not limited to the above examples and application examples, i.e. the invention is not necessarily limited to the above examples and application examples. It should be apparent to those skilled in the art that any modifications of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., fall within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.
Claims (23)
1. The direct-vat-set fermentation microbial inoculum for relieving constipation-type irritable bowel syndrome is characterized by comprising, by weight, 25-32 parts of streptococcus thermophilus ST81 with the preservation number of CGMCC No.15752, 1.5-2 parts of lactobacillus bulgaricus LB42 with the preservation number of CGMCC No.15751, 2.5 parts of bifidobacterium lactis BLa with the preservation number of CGMCC No.15410 and 18-36 parts of a protective agent;
the protective agent comprises, by weight, 12-18 parts of trehalose, 2.5-8.5 parts of maltodextrin, 1.0-1.5 parts of beta-cyclodextrin, 2-5 parts of sucrose, 1.2-2.4 parts of glycerol, 0.01-0.3 part of mannitol and 0.25 part of tween-800.02.
2. The direct-vat set starter for alleviating constipation-predominant irritable bowel syndrome according to claim 1, wherein the viable count of bifidobacterium lactis BLa80 in said direct-vat set starter for alleviating constipation-predominant irritable bowel syndrome is 1X 10 11 cfu/g or more.
3. A method for preparing the direct vat set starter for relieving constipation-predominant irritable bowel syndrome according to claim 1 or 2, comprising the steps of:
(1) Culturing and activating Streptococcus thermophilus ST81, and fermenting to obtain Streptococcus thermophilus ST81 fermented product; culturing and activating Lactobacillus bulgaricus LB42, and fermenting to obtain Lactobacillus bulgaricus LB42 fermented product; culturing and activating the bifidobacterium lactis BLa80, and fermenting to obtain a bifidobacterium lactis BLa80 fermentation product;
(2) Mixing the streptococcus thermophilus ST81 fermentation product, the lactobacillus bulgaricus LB42 fermentation product and the bifidobacterium lactis Bla80 fermentation product obtained in the step (1) with a protective agent to obtain the direct-vat type fermentation microbial inoculum for relieving constipation type irritable bowel syndrome.
4. The process according to claim 3, wherein the temperature of the culture of Streptococcus thermophilus ST81, the temperature of the culture of Lactobacillus bulgaricus LB42 and the temperature of the culture of Bifidobacterium lactis BLa80 in step (1) are each independently 35 to 40 ℃.
5. The method according to claim 3, wherein the time for culturing Streptococcus thermophilus ST81, the time for culturing Lactobacillus bulgaricus LB42 and the time for culturing Bifidobacterium lactis Bla80 in step (1) are each independently 16 to 24 hours.
6. The process according to claim 3, wherein the fermentation temperature of Streptococcus thermophilus ST81 in step (1), the fermentation temperature of Lactobacillus bulgaricus LB42 and the fermentation temperature of Bifidobacterium lactis BLa80 are each independently 35 to 40 ℃.
7. The process according to claim 3, wherein the fermentation time of Streptococcus thermophilus ST81, the fermentation time of Lactobacillus bulgaricus LB42 and the fermentation time of Bifidobacterium lactis BLa80 in step (1) are each independently 9 to 12 hours.
8. The process according to claim 3, wherein the pH of the system during fermentation of Streptococcus thermophilus ST81 in step (1), the pH of the system during fermentation of Lactobacillus bulgaricus LB42 and the pH of the system during fermentation of Bifidobacterium lactis Bla80 are each independently 5.5 to 6.0.
9. The method of claim 3, wherein the fermentation product of step (1) after fermentation of streptococcus thermophilus ST81, after fermentation of lactobacillus bulgaricus LB42 and after fermentation of bifidobacterium lactis BLa80 further optionally comprises centrifugation.
10. The method of claim 9, wherein the rotational speeds of the centrifuges are each independently 6000 to 10000r/min and the times of the centrifuges are each independently 10 to 15min.
11. The method of claim 3, wherein said mixing in step (2) further comprises drying.
12. The method of claim 11, wherein the drying is freeze-drying.
13. Use of the direct vat set starter for alleviating constipation-predominant irritable bowel syndrome according to claim 1 or 2 in the preparation of a fermented food, wherein the inoculation amount of the direct vat set starter for alleviating constipation-predominant irritable bowel syndrome in the fermented food is 20-50g/T.
14. The use according to claim 13, wherein the fermented food product comprises any one of fermented soy milk, fermented soy flour, fermented milk or fermented milk powder.
15. Fermented soybean milk for relieving constipation-predominant irritable bowel syndrome, wherein the raw materials for preparing the fermented soybean milk for relieving constipation-predominant irritable bowel syndrome comprise soybean flour, gum base, water and the direct-vat-set fermentation inoculant for relieving constipation-predominant irritable bowel syndrome according to claim 1 or 2.
16. The fermented soybean milk for relieving constipation-predominant irritable bowel syndrome according to claim 15, wherein the raw materials for preparing the fermented soybean milk for relieving constipation-predominant irritable bowel syndrome comprise, by mass, 0.002-0.005% of a direct-vat starter for relieving constipation-predominant irritable bowel syndrome, 10-28% of soybean flour, 3-20% of a gum base, and the balance water.
17. The fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome of claim 15, wherein the gum base comprises any one or a combination of at least two of coconut milk, white sugar, agar, pectin, citrus fiber, or sea salt.
18. The fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome of claim 17, wherein the gum base comprises coconut milk, white sugar, agar, pectin, citrus fiber, and sea salt.
19. The fermented soybean milk for alleviating constipation-predominant irritable bowel syndrome of claim 18, wherein the gum base comprises, in parts by weight, 3-10 parts of coconut milk, 1-5 parts of white sugar, 0.1-1 part of agar, 0.1-0.8 part of pectin, 0.2-0.8 part of citrus fiber and 0.01-0.1 part of sea salt.
20. A method for preparing fermented soybean milk for relieving constipation-predominant irritable bowel syndrome according to any one of claims 15-18, comprising mixing bean flour, gum base and water, homogenizing, sterilizing, inoculating a direct-vat-set fermentation starter for relieving constipation-predominant irritable bowel syndrome, fermenting, and demulsifying to obtain the fermented soybean milk for relieving constipation-predominant irritable bowel syndrome.
21. The method of claim 20, wherein the temperature of the mixing is 60-90 ℃.
22. The method of claim 20, wherein the temperature of the seeding is 38-50 ℃.
23. The method of claim 20, wherein the fermentation temperature is 38-50 ℃.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111293299.0A CN114045233B (en) | 2021-11-03 | 2021-11-03 | Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111293299.0A CN114045233B (en) | 2021-11-03 | 2021-11-03 | Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114045233A CN114045233A (en) | 2022-02-15 |
CN114045233B true CN114045233B (en) | 2024-02-27 |
Family
ID=80206991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111293299.0A Active CN114045233B (en) | 2021-11-03 | 2021-11-03 | Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114045233B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114146101B (en) * | 2021-11-22 | 2023-07-07 | 微康益生菌(苏州)股份有限公司 | Application of bifidobacterium animalis subspecies lactis BLa80 in preparation of medicines or foods for regulating intestinal motility |
CN114480208B (en) * | 2022-02-18 | 2023-09-29 | 微康益生菌(苏州)股份有限公司 | Direct-vat-set probiotic starter for relieving immune disorder and application thereof |
CN115558620B (en) * | 2022-09-30 | 2023-10-20 | 微康益生菌(苏州)股份有限公司 | Lactic acid bacteria freeze-drying protective agent and preparation method and application thereof |
CN117736943B (en) * | 2024-02-20 | 2024-05-24 | 山东中科嘉亿生物工程有限公司 | Composite microbial agent for improving irritable bowel syndrome and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893214A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder |
CN111466440A (en) * | 2020-06-03 | 2020-07-31 | 金华银河生物科技有限公司 | Probiotic fermented milk capable of relieving constipation |
-
2021
- 2021-11-03 CN CN202111293299.0A patent/CN114045233B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103893214A (en) * | 2014-03-28 | 2014-07-02 | 北京和美科盛生物技术有限公司 | Probiotics viable bacteria powder produced by whole oat solid-state mixed fermentation and preparation method of probiotics viable bacteria powder |
CN111466440A (en) * | 2020-06-03 | 2020-07-31 | 金华银河生物科技有限公司 | Probiotic fermented milk capable of relieving constipation |
Also Published As
Publication number | Publication date |
---|---|
CN114045233A (en) | 2022-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114045233B (en) | Direct-vat fermentation microbial inoculum for relieving constipation type irritable bowel syndrome and preparation method and application thereof | |
EP3530277A1 (en) | Chinese medicine healthcare preparations for slimming and weight loss | |
CN110946913B (en) | Probiotic composition for relieving constipation and hemorrhoids | |
CN112999261B (en) | Natto fermented composition capable of relieving arteriosclerosis and preparation method and application thereof | |
WO2013127146A1 (en) | Lactobacillus plantarum able to relieve lead toxicity and use thereof | |
CN106798252B (en) | Natto product with effects of regulating intestines and stomach, reducing blood fat and dissolving thrombus | |
CN103110861B (en) | Granular preparation for preventing infants from getting inflamed and adjusting intestines and stomach and preparation method thereof | |
CN112040792A (en) | Composition for inducing defecation and losing weight and preparation method thereof | |
CN117487683A (en) | Probiotic composition with effects of resisting claustration, protecting stomach, promoting digestion and removing food retention and application thereof | |
KR20160037510A (en) | Fermented foods improve bowel function and a method of manufactuing stercoral removal efficacy | |
CN110917174A (en) | Oral probiotic capsule for regulating balance of female vaginal flora and preparation method thereof | |
CN106165780A (en) | A kind of broiler Chinese medicine composite probiotics feed additive and preparation method thereof | |
CN111557404A (en) | Digestion-aiding probiotic solid beverage and preparation method thereof | |
KR100716123B1 (en) | Food composition comprising fermented dioscorea batatas decne. and the rhizoma thereof with lactic acid for preventing and improving constipation and obesity | |
CN113974043A (en) | Prebiotics solid beverage and preparation method thereof | |
CN102742653B (en) | Brain-strengthening and nerve soothing probiotic goat milk tablet and preparation method of brain-strengthening and nerve soothing probiotic goat milk tablet | |
CN106798755B (en) | Probiotic composition with function of conditioning hyperplasia of mammary glands and application thereof | |
KR20170072003A (en) | Method of manufacturing a fermented food that can help diabetes using the Hordeum vulgare L. and fermented food that has been produced by it | |
KR20110116344A (en) | Composition for improving bowel function and relieving constipation containing dietary fiber, oligosaccharide and bacillus coagulans | |
CN114452308A (en) | Probiotics protective agent, microecological preparation prepared from same and application of probiotics protective agent | |
CN115462525B (en) | Blood fat regulating composition and preparation method and application thereof | |
KR102165106B1 (en) | A pill or granule comprising Dendropanax Morbifera extract for improving constipation disease and a method for producing the same. | |
CN112999305A (en) | Solid preparation for regulating intestinal flora disturbance and preparation method thereof | |
CN114946954A (en) | Solid beverage of probiotic compound composition containing traditional Chinese medicine components and preparation method | |
CN111165826A (en) | Probiotic composition for improving renal function health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |